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Replicating and nonreplicating nucleic acid-based vaccines as well as Semliki Forest-recombinant Viruses (rSFVs) were
evaluated for the development of a vaccine against hepatitis C virus (HCV). Replicating SFV-DNA vaccines (pSFV) and rSFVs
expressing HCV core or E2 antigens were compared with classical CMV-driven plasmids (pCMV) in single or bimodal vaccine
protocols. In vitro experiments indicated that all vaccine vectors produced the HCV antigens but to different levels depending
on the antigen expressed. Both replicating and nonreplicating core-expressing plasmids induced, upon injection in mice,
specific comparable CTL responses ranging from 10 to 50% lysis (E:T ratio 100:1). Comparison of different injection modes
(intramuscular versus intraepidermal) and the use of descalating doses of DNA (1–100 mg) did not show an increased efficacy
of the core–SFV plasmid compared with the CMV-driven one. Surprisingly, rSFVs yielded either no detectable anticore CTL
or very low anti-E2 antibody titers following either single or bimodal administration together with CMV-expressing counter-
parts. Prime-boost experiments revealed, in all cases, the superiority of DNA-based only vaccines. The anti-E2 antibody
response was evaluated using three different assays which indicated that all generated anti-E2 antibodies were targeted at
similar determinants. This study emphasizes the potential of DNA-based vaccines for induction of anti-HCV immune
responses and reveals an unexpected and limited benefit of SFV-based vaccinal approaches in the case of HCV core and E2.
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The development of a vaccine against hepatitis C virus
(HCV), the principal agent of transfusion-associated and
community acquired non-A, non-B hepatitis worldwide
(Kuo et al., 1989) represents an impressive challenge.
mmune correlates of protection are yet poorly defined
for review (Abrignani, 1997; Chang et al., 1997)) and will
emain such, at least in the near future, for reasons both
elated to the intrinsic nature of the virus itself and the
xperimental context existing to date. The high plasticity
f the viral genome (known to exist as quasi-species
Bukh et al., 1995)), has been shown to be responsible for
he emergence of mutants capable of escaping both the
umoral- and the cellular-mediated immune response
evelop by the host (Chang et al., 1997; Kato et al., 1994;
an Doorn et al., 1995; Weiner et al., 1992), thus rendering
articularly difficult the characterization of dominant pro-
ective determinants. The lack of a reproducible and
ighly productive in vitro replication assay hampers dra-
atically the identification of putative neutralizing anti-
odies. Finally, the absence of a small susceptible ani-
1 To whom reprint requests should be addressed. E-mail: inchauspe@
yon151.inserm.fr.259al model (the chimpanzee is the only species that can
upport HCV replication) precludes the dissection of
rotective or curative vaccinal immune responses.
HCV vaccine studies have relied on the use of purified
ecombinant antigens (Choo et al., 1994; Kakimi et al.,
995; Sallberg et al., 1996), recombinant viruses (Bruna-
omero et al., 1997), and naked DNA-based approaches
for review see (Inchauspe´, 1999)). The latest represents
he largest bulk of data gathered so far. One target of
hoice has been the core protein as it constitutes the
ost conserved viral antigen and has been shown to be
esponsible for induction of CD41- and CD81-mediated
responses in the natural infection (Koziel et al., 1993;
Missale et al., 1996). DNA-based vaccination studies
have documented the induction of either or both anticore
antibody-mediated and cellular-mediated immune re-
sponses, although such responses remain generally
weak. Indeed, multiple injections of the DNA immuno-
gens as well as in vitro stimulation of splenic cells prior
to detection of specific immune responses (cytokines
and CTL) are typically required. Although E2 is a much
less conserved antigen than core (Kato et al., 1994; van
Doorn et al., 1995), anti-E2 antibodies with cross-reactiv-
ity potential have been described (Nakano et al., 1997;
Fournillier et al., 1999).
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260 VIDALIN ET AL.Strategies for optimization of DNA vaccines are cur-
rently under investigation in many laboratories. Suicidal
DNA vaccines described by Berglund et al. are self-
amplifying replicons capable of producing the Semliki
Forest Virus replicase complex from a plasmid template
which catalyzes cytoplasmic self-amplification of the re-
combinant RNA containing the sequence of interest (Ber-
glund et al., 1998). These vectors and similar ones based
on the sindbis virus replicative machinery (Hariharan et
al., 1998) have been shown to elicit significantly stronger
humoral and cellular immune responses than prototype
plasmid vectors. Other recent studies have also begun to
illustrate that particular sequence of vaccinations, involv-
ing different vaccine vehicles, are more efficient at in-
ducing higher antibody titers and/or CTL responses than
the separate use of each vehicle. For example, a protein
boosting following priming with DNA has been shown in
the case of HIV Env protein to increase antibody produc-
tion and protect macaques against an infectious chal-
lenge with SIV (Letvin et al., 1997). Additional protocols
ave illustrated the benefit of boosting with live recom-
inant viruses following DNA priming for induction of
nhanced cellular-mediated immune responses. Inter-
sting data have been obtained recently with fowlpox
iruses in the SIV and HIV models (Kent et al., 1998;
obinson et al., 1999). Alphaviruses, because of their
mall genome size, have been extensively investigated
or use as expression vectors (Frolov et al., 1996). In
particular, immunization with recombinant Semliki Forest
Virus particles (rSFV), that are deficient in the genes
coding for the viral structural proteins and can thus only
undergo a unique round of nonproductive replication
(Liljestro¨m and Garoff, 1991), have proven efficacious for
induction of antibodies or CTL directed against the en-
coded foreign antigen (Zhou et al., 1994, 1995).
We have investigated here the potentials that can offer
the SFV replicative machinery in the design of a vaccine
against HCV. Two approaches were evaluated: SFV-de-
rived self-replicating DNAs in comparison with conven-
tional CMV-driven plasmids and the use of rSFV particles
in prime-boosting experiments in combination with na-
ked DNAs. Two HCV antigens were selected: the core
and the envelope glycoprotein E2. The comparative vac-
cine potential of the different immunogens was evalu-
ated through the testing of specific cytotoxic T lympho-
cytes and anti-HCV antibodies.
RESULTS
Comparison of SFV-derived replicating DNAs and
conventional CMV-driven plasmids for induction
of anticore and anti-E2 immune responses
In vitro expression studies. Transient transfection ex-
periments followed by immunofluorescence staining
showed that all plasmids expressed the encoded HCV
antigens (Fig. 1A) as well as, in the case of SFV-derived
DNAs, the SFV replicase. bThe transfection efficiency of the SFV plasmids, eval-
uated in LTK2 cells, was found to be 3 to 4 times lower
than that of the CMV counterparts (data not shown), a
likely reflection of the larger size of the pSFV plasmids.
The intracellular core and E2 expression levels of the
SFV- and the CMV-driven plasmids were compared using
specific capture ELISAs (data not shown). They revealed
equivalent production of HCV core when expression was
derived from the SFV plasmid in comparison with that
observed with the CMV plasmid, while expression of E2
was only detected following transfection with the CMV
plasmid. Neither core or E2 could be visualized when
Western blot analysis was performed using cell extracts
from transfected cells.
Induction of cytotoxic T lymphocytes (CTL) targeted at
HCV core. The capacity of the CMV- and the SFV-based
plasmids at inducing core-specific CTL was compared in
the context of two injection routes: intramuscular (i.m.,
Fig. 2A) and intraepidermal (i.e., Fig. 2B). BALB/c mice
were injected three times (at 0, 2, 7 weeks) and CTL
analyzed 5, 7, and 10 weeks after the primo-injection
(p.i.). Both injection routes and plasmids yielded a de-
tectable CTL activity. One hundred percent of the mice
developed core-specific CTL at Week 7 with either injec-
tion route or plasmid and those were still detectable at
Week 10 p.i. Although our data were gathered from bulk
analysis and therefore not quantitative, there appeared
to be a trend toward a weaker response in the group
injected with pSFVC. In addition, while 100% of the mice
from groups injected with the pCMVC2 developed a
detectable CTL response, this was not always the case
for groups of mice injected with the pSFV one (Figs. 2A
and 2B).
Injection of descalating doses of either CMV- or SFV-
driven DNAs result in the induction of substantial but
comparable core specific CTL. To further compare the
two core-expressing plasmids, decreasing doses of DNA
(100, 10, and 1 mg) were injected using the i.m. route in
mice. Animals received a booster injection at Week 2 and
CTL were analyzed two weeks later (Fig. 3). Both plas-
mids were capable of inducing specific anticore CTL
when as little as 1 mg was injected (C and F). Specific
lysis ranged from 20% (in the pSFV-injected group using
1 mg) to 80% (in the pCMV-injected group using 100 mg).
Overall, CTL tended to be weaker using the pSFV plas-
mid as mice immunized with 1 mg of pCMV-C2 could
develop higher CTL than mice immunized with 100 mg of
SFV.C (Figs. 3C and 3D).
Humoral immune responses. No anticore antibodies
ere detected following vaccination with either types of
lasmids (a result similar to recombinant adenovirus
article immunization recently described by Lasarte et al.
1999)) and only mice injected with the CMV-driven E2
lasmid (pCI.E2t) seroconverted to anti-E2 antibodies as
reviously observed (Fournillier et al., 1999; Fournillier et
l., 1998; data not shown). Surprisingly, no anti-E2 anti-
odies were detected following vaccination with the
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m
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261SEMLIKI FOREST VIRUS VACCINES FOR HCVpSFV-E2t plasmid (data not shown) reflecting either a
poor expression level from the pSFV plasmid as seen in
vitro (see above) or the induction of antibodies of a
different nature than those detectable with the ELISA
assay used.
Single and bimodal vaccination using recombinant
SFV (rSFV) particles expressing core and E2 and
CMV-driven counterpart plasmids
In vitro expression studies. Immunofluorescence stud-
ies following infection of cells with either rSFV core or
rSFV-E2t viruses showed that both vectors expressed the
expected HCV antigens (Fig. 1B). Western blot and im-
munoprecipitation studies were also performed follow-
ing infection of cells with either rSFV viruses. As shown
in Fig. 4, cell extracts contained the 21-kDa core protein
(A) or the 58-kDa E2 antigen (B), while mock-infected
derived extracts showed no reactivity to the specific HCV
FIG. 1. (A) Immunostaining of LTK2 cells transfected with the differe
ase of SFV-derived DNAs, the SFV replicase expression, was perfor
onoclonal antibody against the nsp2 protein (replicase) of SFV as desc
ith the rSFV expressing core or E2.antibodies.Using the above described specific capture ELISA, we
observed that expression of HCV core following infection
of cells with the rSFV core was similar or higher than that
seen with the pCMVC2 plasmid but that of E2 expressed
after infection with the rSFV-E2t was undetectable (data
not shown).
Immunization studies. Single and bimodal administra-
tion of CMV-driven plasmids (pCMV-C2 or pCI.E2t) and
rSFV particles expressing HCV core and E2 antigens
were performed in BALB/c mice. Four different immuni-
zation schedules were followed: priming with DNA and
boosting either with DNA (DNA 1 DNA) or rSFV (DNA 1
rSFV), priming with rSFV and boosting either with DNA
(rSFV 1 DNA) or rSFV (rSFV 1 rSFV). Alternatively, a third
booster injection was performed of the same nature as
the second one (e.g., DNA 1 DNA 1 DNA). All DNA were
injected using the i.e. route, while all rSFV particles were
injected intravenously. CTL responses were analyzed 2
-expressing plasmids. Analysis of HCV core and E2 as well as, in the
ith a murin monoclonal anticore antibody, anti-E2 antisera, or a mice
nder Materials and Methods. (B) Immunostaining of BHK cells infectednt HCV
med w
ribed uweeks following the latest injection, while anti-E2 anti-
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262 VIDALIN ET AL.bodies were evaluated at 0, 5, and 14 weeks post primo-
injection.
Induction of anticore specific CTL. As illustrated in Fig.
5A, following two immunizations, a core-specific CTL
response was observed only when the primo-injection
was done using plasmid DNA (panel DNA 1 DNA). In
addition, the response was more readily detected when
the two injections were performed with DNA only rather
FIG. 2. Cytotoxic T-Lymphocyte activity following (A) intramuscular
(lower) vactor. Mice were immunized three times (at 0, 2, 7 weeks) w
performed at 5, 7, and 10 weeks following the primo-injection.than when a rSFV boost was included (panels DNA 1 irSFV or rSFV 1 DNA). Vaccination using rSFV-core alone
id not yield any detectable CTL (panel rSFV 1 rSFV). A
econd booster injection did not result in either in-
reased specific lysis (when those were already de-
ected after one booster injection) or in the appearance
f core-specific CTL in the context of a rSFV-based im-
unization only (Fig. 5B). Taken together, these results
ndicate that a combined DNA/rSFV vaccination regimen,
ntraepidermal immunization with the pCMV-C2 (upper) or the pSFV.C
mg (i.m. injection) or 5 mg (i.e. injection) of DNA. CTL analysis wasor (B) i
ith 100ndependent of the sequence of administration, did not
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263SEMLIKI FOREST VIRUS VACCINES FOR HCVimprove the induction of anticore CTL observed following
a simple DNA vaccination. The highest number of mice
developing a detectable anticore CTL response was al-
ways and systematically found in the DNA-only injected
groups (3:3 mice, panel A, DNA 1 DNA or 2:3 mice, panel
, DNA 1 DNA 1 DNA). Surprisingly, the data revealed
he incapacity of rSFV-core particles to induce detectable
ore CTL.
Humoral responses. Anticore and anti-E2 antibodies
ere evaluated in groups of BALB/c mice injected under
he four different vaccine regimens described above. As
reviously observed with the nucleic acid-based vac-
ines, no detectable anticore antibodies were observed
nder any of the regimens used. Three kinds of assays
ere performed to characterize the anti-E2 induced re-
ponse.
First, a specific standard ELISA (INNO-test) using a
urified E2 protein expressed and purified from mamma-
ian cells was used (Fig. 6). All four groups of animals
isplayed detectable anti-E2 antibodies but with major
ifferences: the highest anti-E2 titers were observed in
he group immunized with E2-DNA only (mean titer:
:105612). The group of mice that received two DNA
njections, following a priming with the rSFV-E2t, yielded
lso high anti-E2 antibody titers (mean titer: 1:91210). In
sharp contrast, groups of mice that received either two or
three rSFV injections yielded very low or no detectable
anti-E2 antibodies (mean titer: 1:12116 and 1:1663, re-
spectively). This lack of antibody reactivity was also
reflected in the second test implemented. As shown in
the figure, when HCV-VLPs were used to analyze the
FIG. 3. Cytotoxic T-lymphocyte activity following intramuscular immu
E, F). Mice were immunized via the i.m. route using 100 mg (A, D), 10 mg
analysis was performed at 4 weeks following primo-injection. Resultsnization with decreasing doses of the vector pCMV-C2 (A, B, C) or pSFV.C (D,
(B, E), or 1 mg (C, F) of the respective DNAs and boosted 2 weeks later. CTL
are shown for three to four individually vaccinated mice.mice sera, only those obtained from mice immunizedFIG. 4. Western blot and immunoprecipitation analysis of BHK cell
extracts infected with rSFV particles. (A) Soluble and insoluble fractions
(SF and IF, respectively) of rSFV-C infected cell lysates were subjected
to electrophoresis on a 12% gel, transferred to a nitrocellulose mem-
brane, incubated with an anticore mouse monoclonal antibody, and
assayed with the ECL system (Pierce, Rockford, IL). (B) rSFV.E2t-
infected cell lysates labeled with [35S] methionine were immunopre-
cipitated with a specific anti-E2 mouse monoclonal antibody and sam-
ples analyzed by SDS-PAGE (12% polyacrylamide). Positions of protein
molecular weight markers are indicated on the left and those of HCV
proteins on the right sides of the figure.
264 VIDALIN ET AL.with two or three DNA injections showed a specific,
detectable reactivity while those derived from regimens
including two or three rSFV boosts failed to demonstrate
the presence of anti-VLP antibodies. Thus, we observed a
correlation between anti-E2 titers observed in the standard
E2-ELISA and that observed using the VLP-based assay.
In an attempt to further characterize the nature of the
anti-E2 antibodies generated in seroconverted mice, we
FIG. 5. Anticore specific cytotoxic lymphocyte activity following bim
determined for individually vaccinated mice following i.e. and/or i.v. imm
boosted once (A) or twice (B) later.looked at the reactivity of sera from anti-E2 positive miceagainst different domains of E2 in immunofluorescence
studies using a panoply of E2-plasmids (see Materials
and Methods and Nakano et al., 1999). Specific signals
were obtained with all wild-type expression plasmids
allowing the narrowing of the epitope reactivity to aa.
466–644 and 384–554, similar to what has been ob-
served with human sera from HCV patients (Nakano et
al., 1999). While such human sera typically recognize
ministration of HCV core DNA and rSFV particle. CTL response was
ions with 5 mg of DNA or 106 rSFV particles per mice, respectively, andodal ad
unizat5:10 E2-glycosylation mutants (Nakano et al., 1999), in
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265SEMLIKI FOREST VIRUS VACCINES FOR HCVaddition to those, three mutants were only specifically
recognized by the mice sera (mutants at positions aa
423, 430, 473). This latter observation suggests that
anti-E2 antibodies induced following vaccination (at least
in mice) can be additional determinants of E2 other than
those recognized by human sera.
Because of the unexpected lack of responses follow-
ing rSFV-CAP or rSFV-E2 immunization and to provide an
independent confirmation of the efficacy of the SFV vec-
tors as vaccine vehicles, controlled mice were injected
with a particle vaccine expressing LacZ (prepared under
the same conditions as those use for preparation of the
HCV-vaccines). As shown in Table 1, anti-b-galactosi-
dase antibodies were observed with all prime-boost vac-
FIG. 6. Anti-E2 antibody ELISA titers at Week 14 postinitial vaccination
Results are shown as the reciprocal of the serum dilution equivalent
control. Antibody titers determined using the INNO test are shown with
on top of the bars for seroconverted mice.
TABLE 1
b-Galactosidase-Specific Antibody Titers
Vaccination protocol Antibody titers
DNA 1 DNA 24,300
DNA 1 rSFV 24,300
rSFV 1 DNA 8,100
rSFV 1 rSFV 24,300
DNA 1 DNA 1 DNA 72,900
DNA 1 DNA 1 rSFV 72,900
rSFV 1 rSFV 1 DNA 8,100
rSFV 1 rSFV 1 rSFV 24,300
Note. Prime-boost experiments were performed as described in Fig.
5 using a plasmid (DNA) and/or rSFV expressing the b-galactosidase.
Anti-b-galactosidase antibodies were tested 15 days following the lastibooster injection.cine conditions tested, including those based solely on
particles (rSFVs). Antibody titers appeared to be in the
range of what is typically observed in rSFV-b-galactosi-
dase immunization (M. Chen, personal communication).
These observations confirm rSFV as proper vaccine ve-
hicles.
DISCUSSION
Different strategies can be explored to optimize im-
mune responses that can be elicited following DNA vac-
cination. Plasmid DNA can be manipulated to direct
antigenic expression to the cell membrane for a better
exposure (Forns et al., 1999), to secretion pathways for
an enhanced B-cell mediated response (Cardoso et al.,
1996; Inchauspe´ et al., 1997), or, for example, to the
proteasome for CD81 T cells optimized responses (Ro-
riguez et al., 1997) or simply directly modified to acquire
elf-replicating properties (Berglund et al., 1998; Hariha-
an et al., 1998). Increasing data illustrate also the benefit
f mixing DNA, in a sequential fashion, with other vac-
ine vehicles to boost and widen immune responses
Fuller et al., 1997; Kent et al., 1998; Letvin et al., 1997;
Robinson et al., 1999). We have in this study dissected
wo such strategies with the goal to optimize DNA-based
accines against HCV: the use of self-replicating plasmid
NA and the combination of naked DNA with a viral-
ased delivery system using SFV.
The use of self-replicating DNAs resulted in either
omparable (anticore CTL) or lower (anti-E2 antibodies)
ing bimodal administration of CMV-driven plasmids and rSFV particles.
he O.D. of sera from mice injected with plasmid and/or rSFV particle
hile anti-envelope antibody titers directed at HCV-VLPs are indicatedfollow
to 33 t
bars wmmune responses against the two model HCV antigens
266 VIDALIN ET AL.chosen in this study. These observations are in contrast
to reports that have shown enhancement of vaccine-
induced immune responses when SFV-replicating DNAs
are used in comparison with CMV-nonreplicating ones
(Berglund et al., 1998; Hariharan et al., 1998). This was
surprising as two major benefits were expected from the
use of DNA replicons : (1) a higher antigenic expression
due to the autocatalytic amplification of the expressed
RNA; (2) the indirect stimulation of cells from the immune
system due to the production of interferons triggered by
the presence of dsRNA in the replicon transfected cells
(Vilcek and Sen, 1996). The in vitro expression of HCV
antigens was in fact not found higher using replicon
DNAs than that obtained with conventional CMV-driven
plasmids. Although the transfection efficiency of the
pSFV plasmids was found to be lower than that of the
pCMV counterparts (three to four times), which may in
part explain the observation made, it remains intriguing
that in contrast to HCV core basically no anti-E2 expres-
sion was detected from the pSFV.E2t plasmid. Either, for
yet uncharacterized reasons, expression of E2 in a pSFV
context is simply very low (preliminary data indicates that
the expression of the SFV replicase is not at least af-
fected by that of the HCV E2 protein; M. Chen, personal
communication) or the nature of the pSFV-E2 expressed
antigen is different and undetectable using the capture
assay that was implemented. Indeed, the lack of signal
observed in the E2-capture ELISA following transfection
with the pSFV.E2t may indicate that the expressed E2 is
not captured by the lectin used in the assay as a result
of a different glycosylation of the antigen. This hypothe-
sis is currently under investigation. As we have shown
and as was previously described, the principal form of
HCV core is insoluble, reflecting the very basic nature of
the protein remaining mostly bound to cell membranes
(for a review see McLauchlan, 2000). This property may
in part explain the absence of antibody response seen
with all of our core immunogens. These observations are
in contrast to those reported by Lagging et al. (1995) and
Saito et al. (1997), who reported a low detection of anti-
capsid antibodies following capsid–DNA immunization.
One difference between their studies and ours are the
boundaries of the HCV sequence expressed (aa 1–191 or
1–170).
Berglund et al. (1998) reported a maximal expression
when an SFV translation enhancer was used (up to three
to five times more for lacZ gene expression when com-
pared with a SFV lacking the enhancer). This enhancer
was not included in our plasmids. On the other hand,
Hariharan et al., using a sinbdis DNA-based vector, did
not find any difference in the expression level of the HSV
gB when compared with a classical CMV plasmid (Hari-
haran et al., 1998). Similarly, Kamrud et al., (1999) ob-
served a low antigenic expression from sinbdis-derived
replicons in the Seoul hantavirus model. The reasons for
this lack of enhanced antigenic expression are not clear.
Nonetheless, despite this surprising limited antigenicexpression, Hariharan et al. reported a clear enhance-
ment of the induction of antibodies and cellular-mediated
immune responses in vaccinated mice in contrast to our
findings and those found by Kamrud et al. (1999). These
observations would suggest that the beneficial effect of
alphavirus DNA-based replicons may be clearly more
dependent on the nature of the antigen expressed rather
than its level of expression. Such nature may influence
the autocatalytic amplification process of the expressed
RNA or, alternatively, the profile of cytokines (in particu-
lar interferons) produced as a consequence of such
process.
The bimodal administration of HCV-DNAs and HCV-
rSFVs, either in the case of core or E2, surprisingly
emphasized the good performance of DNA-based immu-
nization only while it revealed the limitation of rSFV-
based vaccination. This is again in contrast with recent
reports that have clearly illustrated the performance of
recombinant SFV particles at inducing both strong hu-
moral and cellular-immune responses in a variety of
models (Colombage et al., 1998; Fleeton et al., 2000).
rSFV particles failed to induce anticore-specific CTL as
well as anti-E2 antibodies. A study by Lagging et al.
(1995) reports that mice immunized with a recombinant
vaccinia virus expressing HCV structural antigens (in-
cluding core) did not elicit higher lymphoproliferative
responses than that obtained with a conventional pCMV
capsid-driven plasmid underlying the difficulty to en-
hance anticore specific immune response using recom-
binant virus-based approaches. As previously observed
with the pSFV.E2t plasmid, although the expected size
protein is expressed from the rSFV-E2t particles (Fig. 4),
the expression level appears to be also be quite low for
yet uncharacterized reasons. The absence of anticore
CTL remains difficult to explain as expression of core
could be more readily documented than that of E2. The
failure to induce detectable immune responses following
HCV-rSFV vaccination may thus be simply the conse-
quence of a low level of antigenic expression obtained
with these vectors. We overall observed a very low or
absent anti-SFV response whether mice received rSFV-
CAP, rSFV-E2, or rSFV-LacZ (data not shown). Since the
recombinant virus is not replication-competent, this lim-
ited response is not unexpected and in agreement with
observations made using other, non-HCV recombinant
particles (M. Chen, personal communication). The neu-
tralization of particle vaccines by SFV-neutralizing anti-
bodies as a reason for the inefficient induction of HCV
immune responses does not appear to be relevant. Fi-
nally, preliminary data indicate that the CTL precursor
frequency following pCMVC2 immunization is in fact
quite low (1:5 3 105; N. Renard, personal communica-
tion), emphasizing the poor immunogenic nature of
HCV-CAP.
It was interesting to document that DNA vaccination
using a severely truncated form of E2 (pCI.E2t) could
induce anti-E2 antibodies capable of recognizing pre-
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267SEMLIKI FOREST VIRUS VACCINES FOR HCVsumed conformational structures such as presented by
the HCV-VLPs (Baumert et al., 1998, 1999). We had pre-
iously shown (Fournillier et al., 1999) that pCI.E2t, fol-
owing gene gun injection, was capable of inducing NOB
ntibodies (Rosa et al., 1996). Both observations suggest
hat pCI.E2t may be an interesting vaccine component. In
articular, as our epitope mapping study indicates that
CI.E2t-induced antibodies target, in addition, to deter-
inants recognized in the natural infection other deter-
inants not recognized, at least in the context of a
hronic infection, a property that may be worth exploiting
n a vaccine development.
In conclusion, while our study confirms and extends
revious observations outlining the performance of HCV-
ased DNA vaccines (in particular for E2), it reveals
nexpected limitations of SFV-based DNA or rSFV parti-
les. It seems clear to date, as pointed out by a number
f studies, that a major component when using a new
accine vector is the nature itself of the antigen ex-
ressed. In the case of HCV, further studies are war-
anted to unravel the apparent complex relationship
etween core and E2 and the SFV-derived expression
achinery.
MATERIALS AND METHODS
ice
Female BALB/c (H-2d) mice, 6 to 8 weeks old, were
urchased from Charles River (Saint Aubin-les-Elbeufs,
rance).
xpression plasmids
HCV core (aa 1–70) and E2 (aa 340–674) sequences
ere amplified from a vector containing the full-length
DNA sequence of the HCV-H strain (1a) (Inchauspe´ et
l., 1991) and cloned under control of the cytomegalovi-
us (CMV) promoter into the pCMVb plasmid (Clontech,
alo Alto, CA) in the case of core yielding the pCMVC2
lasmid, or into the pCI vector (Promega, Charbonie`re,
rance) in the case of E2 yielding the pCI.E2t plasmid
Fournillier et al., 1999; Vidalin et al., 1999). For vectors
xpressing the HCV genes under the dependence of a
emliki Forest Virus promoter, HCV sequences (aa 1–170
or the core and aa 340–674 for E2) were cloned into the
amHI site of the pBK-SFV1 vector (Liljestro¨m and Garoff,
991) yielding plasmids pBK-SFV.C and pBK-SFV.E2t. All
lasmid-cloned fragments were verified by sequencing.
ecombinant Semliki Forest Viruses
Packaging of recombinant RNAs expressing the HCV
ore and E2 (of identical aa boundaries as those used in
he above described plasmids) was performed according
o described procedures (Berglund et al., 1998; Smerdou
nd Liljestro¨m, 1999). Briefly, two helper RNAs express-
ng the SFV capsid protein and the SFV envelope pro-
eins, respectively, were cotransfected in BHK cellsogether with the HCV-recombinant RNAs. Titration of
nfectious units (IU) by immunofluorescence was per-
ormed as described elsewhere (Liljestro¨m and Garoff,
994).
n vitro studies
LTK2 cells were transfected with the various plasmids
sing the LipofectAMINE PLUS™ reagent (Life Technol-
ogy, Cergy Pontoise, France). The day before trans-
fection, 7 3 105 cells per six-well dish plates were
seeded. HCV-expressing plasmids were transfected us-
ing equimolar quantities of DNA (ranging from 2 to 6.5
mg) and corresponding volumes of PLUS reagent and
LipofectAMINE and incubated 3 h with transfection me-
dium. At 24 or 48 h posttransfection, cells were har-
vested for quantification of DNA or antigenic expression
or for immunofluorescence studies. Infection of cells with
the HCV-rSFVs were performed in BHK cells using
rSFV-C or rSFV.E2t at an m.o.i. of 20 pfu/cell. After 1 h at
37°C, the inoculum was removed and replaced with
Glasgow medium supplemented with 5% FCS. At 12 h
postinfection, the cells were incubated for 12 h with
medium containing 60 mCi/ml [35S] methionine.
For quantification of antigenic expression, cells pellets
ere incubated 30 min at 4°C in lysis buffer (50 mM
ris-HCl (pH 8), 150 mM NaCl, 0.1% SDS, 1% NP40, 0.5%
a-deoxycholate, and 10 mg/ml aprotinin). Lysates were
pun and supernatants used in a core-specific quantita-
ive ELISA as previously described (Jolivet-Reynaud et
l., 1998). Expression of E2 antigen was examined in cell
xtracts using a capture ELISA. Cell lysates were used at
1/20 dilution to coat microtiter plates to which GNA
ectin was adsorbed. E2 was detected by incubation with
pecific monoclonal antibodies at 1 mg/ml, which in its
turn is developed using a goat anti-mouse peroxidase
conjugate (Fournillier et al., 1998). The E2 concentration
was deduced after comparison with the titration of a
standard purified E2 protein.
For immunoprecipitation and Western blot analysis,
rSFV infected cells were lysed with 50 mM Tris-HCl (pH
8), 150 mM NaCl, 0.1% SDS, 1% NP40, 1mM EDTA, and 10
mg/ml aprotinin and then clarified by centrifugation. Su-
pernatants (soluble fraction) were directly used for West-
ern blot or immunoprecipitation analysis while pellets
were further incubated in triple-detergent lysis buffer
described above before testing (insoluble fraction). Anal-
yses were performed as previously described (Dubuis-
son et al., 1994) using anticore or anti-E2 mice monoclo-
nal antibodies.
For immunofluorescence studies, transfected cells
were stained using a purified murin monoclonal anticore
antibody (14C12F5, courtesy of M. Jolivet) or specific
rabbit anti-E2 antisera described previously (Fournillier
et al., 1998), as well as a mice monoclonal antibody
anti-nsp2 protein (replicase) of SFV.
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268 VIDALIN ET AL.Immunizations
All DNA preparations were generated using Qiagen
purification columms (Qiagen, Hilden, Germany). For in-
traepidermal immunizations, plasmid DNA coated on
gold particles (2.6 mm) were accelerated into the abdom-
inal epidermis of mice using a helium-powered Accell227
instrument (PowderJect Inc., Madison, WI). Mice were
immunized with two shots containing 2.5 mg of DNA
each as described (Nakano et al., 1997). For intramuscu-
lar immunization, each tibialis anterior muscle was
treated with 50 ml of cardiotoxin solution (10 mM) five
days before the first immunization. Mice were then im-
munized with 50 ml of DNA in PBS in each pretreated
tibialis anterior.
Synthetic peptide
A synthetic peptide (G10 L) corresponding to a previ-
ously described core CTL epitope (Shirai et al., 1994)
was synthesized by Neosystem (Strasbourg, France).
Cytotoxicity assay
Spleen cells from individual mice, 10 3 106/well in
4-well culture plates were stimulated for 5 days in vitro
ith 10 mM of peptide in alpha MEM culture medium
(Life Technologies) supplemented with 10% fetal calf
serum (Eurobio, Les Ulis, France), 10 mM HEPES buffer,
5 3 1025 M 2-mercaptoethanol, 4 mM L-glutamine, 80
/ml penicillin, 80 mg/ml streptomycin, and nonessential
mino acids (Life Technologies) containing 10 U/ml re-
ombinant IL2 (Pedro-Tech EC LTD). Cells were stimu-
ated again using irradiated syngenic splenocytes
ulsed with the selected peptide G10L and IL2 (10 U/ml,
edro-Tech EC LTD, London, England) on Day 5. On Day
, the stimulated cells were used as effectors in a CTL
ssay.
CTL activity was determined in a standard 51Cr release
assay using U-bottom 96-well plates containing 5000
51Cr-labeled target cells per well. Target cells were p815
ells pulsed with the selected peptide during the labeling
ime. After 1.5 h incubation at 37°C with 51Cr, cells were
washed three times and used in the CTL assay. Effector
cells and target cells were cocultured in duplicate and
supernatants were harvested after 4 h. 51Cr release was
measured using a g-Cobra II counter (Packard, Rungis,
France). The percentage specific cytotoxicity was deter-
mined by the formula: (release in assay 2 spontaneous
release)/(maximum release 2 spontaneous release) 3
100. Control mice were injected with empty plasmids,
pCMVb, pCI, or pBK-SFV1.
etection of anti-E2 antibodies
Induced antibodies were first measured using a spe-
ific ELISA (INNO-test, Innogenetics, Ghent, Belgium).
riefly, recombinant E2 protein, expressed and purifiedrom mammalian cells, were adsorbed to microtiterlates. After blocking, a serial dilution of the samples
as administered to the wells. A standard consisting of
mixture of three monoclonal antibodies directed
gainst E2 was titrated along with the samples. The
uantification in micrograms per milliliter is calculated
ased on those dilutions of the samples given an optical
ensity (OD) in the linear range of the standard. Antibody
iters were calculated as the serial threefold dilution
hich gave an OD that equaled the cut off. The cut-off
alue was established as two times the mean OD of the
lank in the assay (control mice). Anti-E2 antibodies
ere also tested in an ELISA assay performed using
CV Virus Like Particles (VLPs) expressed in baculovirus
s recently described (HCV-LP ELISA; Baumert et al.,
999).
Epitope mapping of E2-containing mice sera was per-
ormed by means of immunofluorescence studies using
lasmids expressing various modified forms of E2 as
escribed by Nakano et al. (1999). Briefly, human malig-
ant melanoma cells (Mewo) were transfected with plas-
ids expressing either wild-type truncated E2 se-
uences of the H isolate (a total of 34 plasmids contain-
ng HCV sequences mapping from aa 384–674) or
xpressing glycosylation mutants of E2 (at positions aa
17, 423, 430, 448, 476, 532, 540, 556, 576, and 623,
espectively). Immunofluorescence analysis was per-
ormed with individual sera from seroconverted mice.
Anti-LacZ IgG titration. Anti-b-galactosidase antibod-
es were tested as previously described (Berglund et al.,
998).
REFERENCES
Abrignani, S. (1997). Immune responses throughout hepatitis C virus
(HCV) infection: HCV from the immune system point of view. Springer
Sem. Immunopathol. 19, 47–55.
Baumert, T. F., Ito, S., Wong, D. T., and Liang, T. J. (1998). Hepatitis C
virus structural proteins assemble into viruslike particles in insect
cells. J. Virol. 72(5), 3827–3836.
Baumert, T. F., Vergalla, J., Satoi, J., Thomson, M., Lechmann, M., Herion,
D., Greenberg, H. B., Ito, S., and Liang, T. J. (1999). Hepatitis C
virus-like particles synthesized in insect cells as a potential vaccine
candidate. Gastroenterology 117(6), 1397–1407.
Berglund, P., Smerdou, C., Fleeton, M. N., Tubulekas, I., and Liljestrom,
P. (1998). Enhancing immune responses using suicidal DNA vac-
cines. Nat. Bio/Technol. 16(6), 562–565.
runa-Romero, O., Lasarte, J. J., Wilkinson, G., Grace, K., Clarke, B.,
Borras-Cuesta, F., and Prieto, J. (1997). Induction of cytotoxic T-cell
response against hepatitis C virus structural antigens using a de-
fective recombinant adenovirus. Hepatology 25, 470–477.
Bukh, J., Miller, R. H., and Purcell, R. H. (1995). Genetic heterogeneity of
hepatitis C virus: quasispecies and genotypes. Sem. Liver Dis. 15,
41–63.
Cardoso, A. I., Blixenkrone-Moller, M., Fayolle, J., Liu, M., Buckland, R.,
and Wild, T. F. (1996). Immunization with plasmid DNA encoding for
the measles virus hemagglutinin and nucleoprotein leads to humoral
and cell-mediated immunity. Virology 225, 293–299.
Chang, K.-M., Rehermann, B., McHutchison, J. G., Pasquinelli, C., South-
wood, S., Sette, A., and Chisari, F. V. (1997). Immunological signifi-
cance of cytotoxic T lymphocyte epitope variants in patients chron-
ically infected by the hepatitis C virus. J. Clin. Invest. 100(9), 2376–
2385.
269SEMLIKI FOREST VIRUS VACCINES FOR HCVChoo, Q.-L., Kuo, G., Ralston, R., Weiner, A., Chien, D., Van Nest, G., Han,
J., Berger, K., Thudium, K., Kuo, C., Kansopon, J., Mc Farlan, J., Tabrizi,
A., Ching, K., Moss, B., Cummins, L. B., Houghton, M., and Much-
more, E. (1994). Vaccination of chimpanzees against infection by the
hepatitis C virus. Proc. Natl. Acad. Sci USA 91, 1294–1298.
Colombage, G., Hall, R., Pavy, M., and Lobigs, M. (1998). DNA-based
and alphavirus-vectored immunisation with prM and E proteins elic-
its long-lived and protective immunity against the flavivirus, Murray
Valley encephalitis virus. Virology 250(1), 151–163.
Dubuisson, J., Hsu, H. H., Cheung, R. C., Greenberg, H. B., Russell,
D. G., and Rice, C. M. (1994). Formation and intracellular localization
of hepatitis C virus envelope glycoprotein complexes expressed by
recombinant vaccinia and Sindbis viruses. J. Virol. 68(10), 6147–6160.
Fleeton, M. N., Liljestrom, P., Sheahan, B. J., and Atkins, G. J. (2000).
Recombinant Semliki Forest virus particles expressing louping ill
virus antigens induce a better protective response than plasmid-
based DNA vaccines or an inactivated whole particle vaccine. J. Gen.
Virol. 81(3), 749–758.
Forns, X., Emerson, S. U., Tobin, G. J., Mushahwar, I. K., Purcell, R. H.,
and Bukh, J. (1999). DNA immunization of mice and macaques with
plasmids encoding hepatitis C virus envelope E2 protein expressed
intracellularly and on the cell surface. Vaccine 17, 1992–2002.
Fournillier, A., Depla, E., Karayiannis, P., Vidalin, O., Vitvitski, L.,
Maertens, G., Tre´po, C., and Inchauspe´, G. (1999). Expression of
noncovalent hepatitis C virus envelope E1/E2 complexes is not
required for the induction of antibodies with neutralizing properties
following DNA immunization. J. Virol. 73(9), 7497–7504.
Fournillier, A., Nakano, I., Vitvitski, L., Depla, E., Vidalin, O., Maertens,
G., Tre´po, C., and Inchauspe´, G. (1998). Modulation of immune re-
sponses to hepatitis C virus envelope E2 protein following injection
of plasmid DNA using single or combined delivery routes. Hepatol-
ogy 28(1), 237–244.
Frolov, I., Hoffman, T. A., Pragai, B. M., Dryga, S. A., Huang, H. V.,
Schlesinger, S., and Rice, C. M. (1996). Alphavirus-based expression
vectors: strategies and applications. Proc. Natl. Acad. Sci. USA
93(21), 11371–11377.
Fuller, D. H., Simpson, L., Cole, K. S., Clements, J. E., Panicali, D. L.,
Montelaro, R. C., Murphey-Corb, M., and Haynes, J. R. (1997). Gene
gun-based nucleic acid immunization alone or in combination with
recombinant vaccinia vectors suppresses virus burden in rhesus
macaques challenged with a heterologous SIV. Immunol. Cell Biol.
75(4), 389–396.
Hariharan, M. J., Driver, D. A., Townsend, K., Brumm, D., Polo, J. M., Belli,
B. A., Catton, D. J., Hsu, D., Mittelstaedt, D., McCormack, J. E.,
Karavodin, L., Dubensky, T. W., Jr., Chang, S. M., and Banks, T. A.
(1998). DNA immunization against herpes simplex virus: enhanced
efficacy using a Sindbis virus-based vector. J. Virol. 72(2), 950–958.
Inchauspe´, G. (1999). DNA vaccine strategies for hepatitis C. J. Hepatol.
30(2), 339–346.
Inchauspe´, G., Vitvitski, L., Major, M. E., Jung, G., Spengler, U., Maison-
nas, M., and Tre´po, C. (1997). Plasmid DNA expressing a secreted or
a nonsecreted form of hepatitis C virus nucleocapsid: comparative
studies of antibody and T-helper responses following genetic immu-
nization. DNA Cell. Biol. 16(2), 182–195.
Inchauspe´, G., Zebedee, S., Lee, D. H., Sugitani, M., Nasoff, M., and
Prince, A. M. (1991). Genomic structure of the human prototype strain
H of hepatitis C virus: comparison with American and Japanese
isolates. Proc. Natl. Acad. Sci. USA 88(22), 10292–10296.
Jolivet-Reynaud, C., Dalbon, P., Viola, F., Yvon, S., Paranhos-Baccala, G.,
Piga, N., Bridon, L., Trabaud, M. A., Battail, N., Sibai, G., and Jolivet,
M. (1998). HCV core immunodominant region analysis using mouse
monoclonal antibodies and human sera: characterization of major
epitopes useful for antigen detection. J. Med. Virol. 56(4), 300–309.
Kakimi, K., Kuribayashi, K., Iwashiro, M., Masuda, T., Sakai, M., Ling, W.,
Kubo, Y., Kobayashi, H., Higo, K., Seki, M., Honda, Y., Yamada, E.,
Matsuura, Y., Miyamura, T., Okuma, M., and Ishimoto, A. (1995).
Hepatitis C virus core region: helper T cell epitopes recognized by
BALB/c and C57BL/6 mice. J. Gen. Virol. 76, 1205–1214.Kamrud, K. L., Hooper, J. W., Elgh, F., and Schmaljohn, C. S. (1999).
Comparison of the protective efficacy of naked DNA, DNA-based
Sindbis replicon and packaged Sindbis replicon vectors expressing
Hantavirus structural genes in hamster. Virology 263, 209–219.
Kato, N., Ootsuyama, Y., Sekiya, H., Ohkoshi, S., Nakazawa, T., Hijikata,
M., and Shimotohno, K. (1994). Genetic drift in hypervariable region 1
of the viral genome in persistent hepatitis C virus infection. J. Virol.
68(8), 4776–4784.
Kent, S. J., Zhao, A., Best, S. J., Chandler, J. D., Boyle, D. B., and
Ramshaw, I. A. (1998). Enhanced T-cell immunogenicity and protec-
tive efficacy of a human immunodeficiency virus type 1 vaccine
regimen consisting of consecutive priming with DNA and boosting
with recombinant fowlpox virus. J. Virol. 72(12), 10180–10188.
Koziel, M. J., Dudley, D., Afdhal, N., Choo, Q. L., Houghton, M., Ralston,
R., and Walker, B. D. (1993). Hepatitis C virus (HCV)-specific cytotoxic
T lymphocytes recognize epitopes in the core and envelope proteins
of HCV. J. Virol. 67(12), 7522–7532.
Kuo, G., Choo, Q.-L., Alter, H. J., Gitnick, G. L., Redeker, A. G., Purcell,
R. H., Miyamura, T., Dienstag, J. L., Alter, M. J., Stevens, C. E.,
Tegtmeier, G. E., Bonino, F., Colombo, M., Lee, W.-S., Kuo, C., Berger,
K., Shuster, J. R., Overby, L. R., Bradley, D. W., and Houghton, M.
(1989). An assay for circulating antibodies to a major etiologic virus
of human non-A, non-B Hepatitis. Science 244, 362–364.
Lagging, L. M., Meyer, K., Hoft, D., Houghton, M., Belshe, R. B., and Ray,
R. (1995). Immune responses to plasmid DNA encoding the hepatitis
C virus core protein. J. Virol. 69, 5859–5863.
Lasaret, J. J., Corrales, F. J., Casares, N., Lopez-Diaz de Cerio, A., Qian,
C., Xie, X., Borras-Cuesta, F., and Prieto, J (1999). Different doses of
adenoviral vector expressing Il-12 enhance or depress the immune
response to a coadministered antigen : the role of nitric oxide.
J. Immunol. 162, 5270–5277.
Letvin, N. L., Montefiori, D. C., Yasutomi, Y., Perry, H. C., Davies, M. E.,
Lekutis, C., Alroy, M., Freed, D. C., Lord, C. I., Handt, L. K., Liu, M. A.,
and Shiver, J. W. (1997). Potent, protective anti-HIV immune re-
sponses generated by bimodal HIV envelope DNA plus protein
vaccination. Proc. Natl. Acad. Sci. USA 94(17), 9378–9383.
Liljestro¨m, P., and Garoff, H. (1991). A new generation of animal cell
expression vectors based on the semliki forest virus replicon. Bio/
Technology 9, 1356–1361.
Liljestro¨m, P., and Garoff, H. (1994). Expression of proteins using Sem-
liki Forest virus vectors. In “Current Protocols in Molecular Biology”
(F. M. Ausubel et al., Ed.), Vol. 2, pp. 16.20.11–16.20.16. Greene
Publishing Associates and Wiley Interscience, New York.
McLauchlan, J (2000). Properties of the hepatitis C virus core protein: a
tructural protein that modulates cellular processes. J. Vir. Hepatitis 7,
2–14.
Missale, G., Bertoni, R., Lamonaca, V., Valli, A., Massari, M., Mori, C.,
Rumi, M. G., Houghton, M., Fiaccadori, F., and Ferrari, C. (1996).
Different clinical behaviors of acute hepatitis C virus infection are
associated with different vigor of the anti-viral cell-mediated immune
response. J. Clin. Invest. 98, 706–714.
Nakano, I., Fukuda, Y., Katano, Y., and Hayakawa, T. (1999). Conforma-
tional epitopes detected by cross-reactive antibodies to envelope 2
glycoprotein of the hepatitis C virus. J. Infect. Dis. 180(4), 1328–1233.
Nakano, I., Maertens, G., Major, M. E., Vitvitski, L., Dubuisson, J.,
Fournillier, A., de Martynoff, G., Tre´po, C., and Inchauspe´, G. (1997).
Immunization with plasmid DNA encoding Hepatitis C virus envelope
E2 antigenic domains induces antibodies whose immune reactivity
is linked to the injection mode. J. Virol. 71(9), 7101–7109.
Robinson, H. L., Montefiori, D. C., Johnson, R. P., Manson, K. H., Kalish,
M. L., Lifson, J. D., Rizvi, T. A., Lu, S., Hu, S. L., Mazzara, G. P., Panicali,
D. L., Herndon, J. G., Glickman, R., Candido, M. A., Lydy, S. L., Wyand,
M. S., and McClure, H. M. (1999). Neutralizing antibody-independent
containment of immunodeficiency virus challenges by DNA priming and
recombinant pox virus booster immunizations. Nat. Med. 5(5), 526–534.
Rodriguez, F., Zhang, J., and Whitton, J. L. (1997). DNA immunization:
ubiquitination of a viral protein enhances cytotoxic T-lymphocyte
RS
S
S
S
v
V
V
W
Z
Z
270 VIDALIN ET AL.induction and antiviral protection but abrogates antibody induction.
J. Virol. 71(11), 8497–8503.
osa, D., Campagnoli, S., Moretto, C., Guenzi, E., Cousens, L., Chin, M.,
Dong, C., Weiner, A. J., Lau, J. Y., Choo, Q. L., Chien, D., Pileri, P.,
Houghton, M., and Abrignani, S. (1996). A quantitative test to estimate
neutralizing antibodies to the hepatitis C virus: cytofluorimetric as-
sessment of envelope glycoprotein 2 binding to target cells. Proc.
Natl. Acad. Sci. USA 93(5), 1759–1763.
aito, T., Sherman, G. J., Kurokohchi, K., Guo, Z-P., Donets, M., Yu,
M-Y. W., Berzofsky, J. A., Akatsuka, T., and Feinstone, S. M. (1997).
Plasmid DNA-based immunization for Hepatitis C virus structural
proteins: immune responses in mice. Gastroenterology 112, 1321–
1330.
allberg, M., Zhang, Z. X., Chen, M., Jin, L., Birkett, A., Peterson, D. L.,
and Milich, D. R. (1996). Immunogenicity and antigenicity of the
ATPase/helicase domain of the hepatitis C virus non-structural 3
protein. J. Gen. Virol. 77(Pt 11), 2721–2728.
hirai, M., Okada, H., Nishioka, M., Akatsuka, T., Wychowski, C.,
Houghten, R., Pendleton, C. D., Feinstone, S. M., and Berzofsky, J. A.
(1994). An epitope in hepatitis C virus core region recognized by
cytotoxic T cells in mice and human. J. Virol. 68(5), 3334–3342.
merdou, C., and Liljestro¨m, P. (1999). Two-helper RNA system for
production of recombinant semliki forest virus particles. J. Virol.
73(2), 1092–1098.an Doorn, L. J., Capriles, I., Maertens, G., DeLeys, R., Murray, K., Kos,
T., Schellekens, H., and Quint, W. (1995). Sequence evolution of the
hypervariable region in the putative envelope region E2/NS1 of
hepatitis C virus is correlated with specific humoral immune re-
sponses. J. Virol. 69(2), 773–778.
idalin, O., Tanaka, E., Spengler, U., Trepo, C., and Inchauspe, G. (1999).
Targeting of hepatitis C virus core protein for MHC I or MHC II
presentation does not enhance induction of immune responses to
DNA vaccination. DNA Cell. Biol. 18(8), 611–621.
ilcek, J. T., and Sen, G. C. (1996). “Interferon and other cytokines.”
Lippincott-Raven, Philadelphia, PA.
einer, A. J., Geysen, H. M., Christopherson, C., Hall, J. E., Mason, T. J.,
Saracco, G., Bonino, F., Crawford, K., Marion, C. D., Crawford, K. A.,
and et al. (1992). Evidence for immune selection of hepatitis C virus
(HCV) putative envelope glycoprotein variants: potential role in
chronic HCV infections. Proc. Natl. Acad. Sci. USA 89(8), 3468–3472.
hou, X., Berglund, P., Rhodes, G., Parker, S. E., Jondal, M., and
Liljestro¨m, P. (1994). Self-replicating semliki forest virus RNA as
recombinant vaccine. Vaccine 12(16), 1510–1514.
hou, X., Berglund, P., Zhao, H., Liljestro¨m, P., and Jondal, M. (1995).
Generation of cytotoxic and humoral immune responses by nonrep-
licative recombinant semliki forest virus. Proc. Natl. Acad. Sci. USA
92, 3009–3013.
